Сложные вопросы лечения воспалительных заболеваний кишечника в реальной клинической практике

Е. Ю. Евдокимова, О. В. Чеснокова, И. Л. Мухина et al. · Pacific Medical Journal · 2019

Objective to analyze the effectiveness of therapy with the use of genetically engineered biologic drugs (GEBD) in patients with moderate and severe forms of ulcerative colitis (UC) and Crohn’s disease (CD). Methods : The study was done based on gastroenterological department of PRCH No. 1. The effectiveness of treatment was assessed with retrospective analysis of 29 case records. The severity of the disease was evaluated according to the Mayo Score and the Harvey–Bradshaw index. Following biologic therapy drugs were used: anti-tumor necrosis factor α agent and integrin blocking agent ‘Vedolizumab’. Clinical response and endoscopic dynamics were included. Data was processed with software Statistica 10. Results : 20 patients were diagnosed with CD, 9 patients – with UC. Mean age of patients is 37.2 y.o. Initially all patients received standard immunomodulatory therapy. Development of resistance to steroids and steroid-dependence, and also ineffectiveness of immunosuppressive drugs became an indication to use GEBD. Positive clinical response was observed right after the first infusion in 24 patients. After 10-14 weeks of treatment positive clinical response was recorded in 58.6 % of cases. After 24–28 weeks of treatment clinical remission rate with endoscopic view improvement was in 24.1 %, and total clinical endoscopic remission rate was 17.2 %. Therapy improvement was required in 17.2 % of cases. Conclusions : The use of GEBD has advantages in clinical and endoscopic remission in treatment of patients with refractory types of UC and CD.

Cited by 0 works. doi:10.17238/pmj1609-1175.2019.3.76-79

Authors